Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772481 | 0.91 | MAPK14 (0.53) | MAPK14HPGDMAPTLMNAMAPK13 | |
| SCHEMBL4132485 | 0.88 | MAPK14 (0.52) | MAPK14HPGDMAPTLMNAMAPK13 | |
| SCHEMBL4145122 | 0.84 | KMT2A (0.48) | MAPK14HPGDCNR1CNR2 | |
| SCHEMBL13772486 | 0.81 | NTRK1 (0.41) | CNR1CNR2 | |
| SCHEMBL13811321 | 0.79 | MAPK14 (0.35) | MAPK14HPGDLMNACNR1CNR2 | |
| SCHEMBL13772488 | 0.79 | SOAT2 (0.62) | MAPT | |
| SCHEMBL13772474 | 0.76 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL4138490 | 0.76 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL4138182 | 0.76 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL4132348 | 0.76 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | MAPK14 1554/4885HPGD 3436/4885MAPT 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.